Oragenics Advances Clinical Trial for Concussion Treatment in New Zealand
April 9, 2025 — Oragenics submits Phase II trial protocol for neurosteroid therapy for mild traumatic brain injury in New Zealand, addressing the need for concussion treatment in the region. Learn more about the company's focus on nasal drug delivery for neurological and infectious diseases.